

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on May 20, 2025

MITF (D3B4T) Rabbit mAb

RRID:AB_2800289

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 97800, RRID:AB_2800289)

Antibody Information

URL: http://antibodyregistry.org/AB_2800289

Proper Citation: (Cell Signaling Technology Cat# 97800, RRID:AB_2800289)

Target Antigen: MITF

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, ChIP, ChIP-seq

Antibody Name: MITF (D3B4T) Rabbit mAb

Description: This monoclonal targets MITF

Target Organism: h, m, mk

Clone ID: Clone D3B4T

Antibody ID: AB_2800289

Vendor: Cell Signaling Technology

Catalog Number: 97800

Record Creation Time: 20241016T222734+0000

Record Last Update: 20241016T225510+0000

Ratings and Alerts

No rating or validation information has been found for MITF (D3B4T) Rabbit mAb.

No alerts have been found for MITF (D3B4T) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Yang S, et al. (2024) The GATOR2 complex maintains lysosomal-autophagic function by inhibiting the protein degradation of MiT/TFEs. *Molecular cell*, 84(4), 727.

Nardone C, et al. (2023) A central role for regulated protein stability in the control of TFE3 and MITF by nutrients. *Molecular cell*, 83(1), 57.

Liu Z, et al. (2023) Kinase Suppressor of RAS 1 (KSR1) Maintains the Transformed Phenotype of BRAFV600E Mutant Human Melanoma Cells. *International journal of molecular sciences*, 24(14).

Song T, et al. (2023) TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy. *The Journal of biological chemistry*, 299(5), 104621.

Kline CD, et al. (2022) MITF Is Regulated by Redox Signals Controlled by the Selenoprotein Thioredoxin Reductase 1. *Cancers*, 14(20).

Carotenuto P, et al. (2022) Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma. *Cell reports*, 41(6), 111601.